COX-2 in the neurodegenerative process of Parkinson's disease

BioFactors

Volumn 38, Issue 6, 2012, Pages 395-397

  Teismann, Peter ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cyclooxygenase 2; Neurodegeneration; Neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CYCLOOXYGENASE 2; DICLOFENAC; INDUCIBLE NITRIC OXIDE SYNTHASE; NEUROTOXIN; OXIDOPAMINE; PEROXIDASE; PROSTAGLANDIN E2; ROFECOXIB;

CELL DEATH; ENZYME ACTIVITY; MICROGLIA; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

CYCLOOXYGENASE 2; HUMANS; NERVE DEGENERATION; PARKINSON DISEASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 84871235128     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1035     Document Type: Review

References (39)

1. Wyss-Coray, T., and Mucke, L. (2002) Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35, 419-432.
2. Hunot, S., Dugas, N., Faucheux, B., Hartmann, A., Tardieu M., et al. (1999) FcεRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19, 3440-3447.
3. McGeer, P. L., Itagaki, S., Boyes, B. E., and McGeer, E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
4. Yamagata, K., Andreasson, K. I., Kaufmann, W. E., Barnes, C. A., and Worley, P. F. (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386.
5. Beiche, F., Klein, T., Nusing, R., Neuhuber, W., and Goppelt-Struebe, M. (1998) Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J. Neuroimmunol. 89, 26-34.
6. Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., et al. (2002) From the cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99, 13926-13931.
7. Warner, T. D., and Mitchell, J. A. (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc. Natl. Acad. Sci. USA 99, 13371-13373.
8. Kis, B., Snipes, J. A., and Busija, D. W. (2005) Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J. Pharmacol. Exp. Ther. 315, 1-7.
9. Qin, N., Zhang, S. P., Reitz, T. L., Mei, J. M., and Flores, C. M. (2005) Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J. Pharmacol. Exp Ther. 315, 1298-1305.
10. Smith, W. L., DeWitt, D. L., and Garavito, R. M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69, 145-182.
11. Landino, L. M., Crews, B. C., Gierse, J. K., Hauser, S. D., and Marnett, L. J. (1997) Mutational analysis of the role of the distal histidine and glutamine residues of prostaglandin-endoperoxide synthase-2 in peroxidase catalysis, hydroperoxide reduction, and cyclooxygenase activation. J. Biol. Chem. 272, 21565-21574.
12. Nelson, C. W., Wei, E. P., Povlishock, J. T., Kontos, H. A., and Moskowitz, M. A. (1992) Oxygen radicals in cerebral ischemia. Am. J. Physiol. 263, H1356-H1362.
13. Chan, P. H. (1996) Role of oxidants in ischemic brain damage. Stroke 27, 1124-1129.
14. Jiang, J., Borisenko, G. G., Osipov, A., Martin, I., Chen, R., et al. (2004) Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells. J. Neurochem. 90, 1036-1049.
15. Li, W., Wu, S., Ahmad, M., Jiang, J., Liu, H., et al. (2010) The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury. J. Neurochem. 113, 965-977.
16. Shimokawa, T., Kulmacz, R. J., DeWitt, D. L., and Smith W. L. (1990) Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J. Biol. Chem. 265, 20073-20076.
17. Yu, Y., Fan, J., Chen, X. S., Wang, D., Klein-Szanto, A. J., et al. (2006) Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat. Med. 12, 699-704.
18. Bove, J., Prou, D., Perier, C., and Przedborski, S. (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2, 484-494.
19. Aubin, N., Curet, O., Deffois, A., and Carter, C. (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71, 1635-1642.
20. Teismann, P., and Ferger, B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174.
21. Teismann, P., Tieu, K., Choi, D. K., Wu, D. C., Naini, A., et al. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. USA 100, 5473-5478.
22. Feng, Z., Wang, T., Li, D., Fung, P., Wilson, B., et al. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329, 354.
23. Knott, C., Stern G., and Wilkin G. P. (2000) Inflammatory regulators in Parkinson's disease: INOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16, 724-739.
24. Hastings, T. G. (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
25. Bazan, N. G. (1999) Eicosanoids, platelet-activating factor and inflammation. In Basic Neurochemistry. (Siegel, G. J., Agranoff, B. W., Albers, R. W., Fisher, S. K., Uhler, M. D., eds.). pp 731, Raven Press Ltd, New York, NY.
26. Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., et al. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281-285.
27. Andreasson, K. (2010) Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat. 91, 104-112.
28. Jin, J., Shie, F. S., Liu, J., Wang, Y., Davis, J., et al. (2007) Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J. Neuroinflammation 4, 2.
29. Carrasco, E., Casper, D., and Werner, P. (2005) Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity. J. Neurosci. Res. 81, 121-131.
30. Shie, F. S., Montine, K. S., Breyer, R. M., and Montine, T. J. (2005) Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 52, 70-77.
31. Carrasco, E., Casper, D., and Werner, P. (2007) PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J. Neurosci. Res. 85, 3109-3117.
32. Kawano, T., Anrather, J., Zhou, P., Park, L., Wang, G., et al. (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med. 12, 225-229.
33. Gendron, T. F., Brunette, E., Tauskela, J. S., and Morley, P. (2005) The dual role of prostaglandin E(2) in excitotoxicity and preconditioning-induced neuroprotection. Eur. J. Pharmacol. 517, 17-27.
34. Williams, J. A., and Shacter, E. (1997) Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and -2. J. Biol. Chem. 272, 25693-25699.
35. Fiebich, B. L., Hull, M., Lieb, K., Gyufko, K., Berger, M., et al. (1997) Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J. Neurochem. 68, 704-709.
36. Hinson, R. M., Williams, J. A., and Shacter, E. (1996) Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 93, 4885-4890.
37. Portanova, J. P., Zhang, Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., et al. (1996) Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med. 184, 883-891.
38. Rojo, A. I., Innamorato, N. G., Martin-Moreno, A. M., De Ceballos, M. L., Yamamoto, M., et al. (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58, 588-598.
39. Rojanathammanee, L., Murphy, E. J., and Combs, C. K. (2011) Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J. Neuroinflammation 8, 44.